Bragg Financial Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,578
| Closed | -$221K | – | 316 |
|
|
2022
Q4 | $221K | Sell |
2,578
-1,199
| -32% | -$94.9K | 0.01% | 303 |
|
|
2022
Q3 | $233K | Sell |
3,777
-2,303
| -38% | -$145K | 0.02% | 284 |
|
|
2022
Q2 | $376K | Sell |
6,080
-2,316
| -28% | -$143K | 0.03% | 248 |
|
|
2022
Q1 | $499K | Sell |
8,396
-4,846
| -37% | -$310K | 0.03% | 237 |
|
|
2021
Q4 | $925K | Hold |
13,242
| – | – | 0.06% | 183 |
|
|
2021
Q3 | $925K | Sell |
13,242
-2,028
| -13% | -$142K | 0.06% | 183 |
|
|
2021
Q2 | $1.05M | Sell |
15,270
-6,452
| -30% | -$431K | 0.07% | 180 |
|
|
2021
Q1 | $1.4M | Sell |
21,722
-3,226
| -13% | -$208K | 0.09% | 166 |
|
|
2020
Q4 | $1.45M | Sell |
24,948
-72
| -0.3% | -$4.34K | 0.13% | 147 |
|
|
2020
Q3 | $1.58M | Buy |
25,020
+104
| +0.4% | +$7.21K | 0.16% | 133 |
|
|
2020
Q2 | $1.92M | Buy |
24,916
+1,212
| +5% | +$92.9K | 0.21% | 123 |
|
|
2020
Q1 | $1.77M | Buy |
23,704
+176
| +0.7% | +$12.2K | 0.24% | 123 |
|
|
2019
Q4 | $1.53M | Sell |
23,528
-2,888
| -11% | -$188K | 0.17% | 142 |
|
|
2019
Q3 | $1.67M | Sell |
26,416
-402
| -1% | -$26.3K | 0.2% | 137 |
|
|
2019
Q2 | $1.81M | Buy |
26,818
+730
| +3% | +$48K | 0.22% | 137 |
|
|
2019
Q1 | $1.7M | Buy |
26,088
+1,917
| +8% | +$127K | 0.22% | 138 |
|
|
2018
Q4 | $1.51M | Buy |
24,171
+1,572
| +7% | +$110K | 0.23% | 134 |
|
|
2018
Q3 | $1.75M | Buy |
22,599
+350
| +2% | +$26.4K | 0.23% | 131 |
|
|
2018
Q2 | $1.58M | Buy |
22,249
+2,021
| +10% | +$143K | 0.22% | 133 |
|
|
2018
Q1 | $1.52M | Sell |
20,228
-266
| -1% | -$21.1K | 0.22% | 138 |
|
|
2017
Q4 | $1.47M | Sell |
20,494
-1,449
| -7% | -$110K | 0.21% | 137 |
|
|
2017
Q3 | $1.78M | Sell |
21,943
-790
| -3% | -$60.4K | 0.27% | 119 |
|
|
2017
Q2 | $1.61M | Buy |
22,733
+1,367
| +6% | +$91K | 0.25% | 126 |
|
|
2017
Q1 | $1.45M | Buy |
21,366
+462
| +2% | +$32.5K | 0.23% | 133 |
|
|
2016
Q4 | $1.5M | Sell |
20,904
-2,899
| -12% | -$215K | 0.25% | 136 |
|
|
2016
Q3 | $1.88M | Buy |
23,803
+175
| +0.7% | +$14.2K | 0.34% | 114 |
|
|
2016
Q2 | $1.97M | Buy |
23,628
+3,234
| +16% | +$287K | 0.36% | 113 |
|
|
2016
Q1 | $1.87M | Buy |
20,394
+3,008
| +17% | +$271K | 0.36% | 114 |
|
|
2015
Q4 | $1.76M | Buy |
17,386
+3,545
| +26% | +$369K | 0.38% | 100 |
|
|
2015
Q3 | $1.36M | Buy |
13,841
+8,711
| +170% | +$967K | 0.33% | 110 |
|
|
2015
Q2 | $601K | Buy |
+5,130
| New | +$561K | 0.14% | 172 |
|
Other funds holding GILD
Bragg Financial Advisors's GILD Position: Q1 2023 in Review
Bragg Financial Advisors sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 2,578 shares — an estimated $221K sold.
Bragg Financial Advisors first reported a position in GILD in Q2 2015 and held it in 31 quarters. The position peaked at $1.97M in Q2 2016. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.
- Bragg Financial Advisors reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
- Bragg Financial Advisors sold 2,578 Gilead Sciences shares in Q1 2023, an estimated $221K.
- Bragg Financial Advisors first reported a position in Gilead Sciences in Q2 2015 and held it in 31 quarters.
- Bragg Financial Advisors's Gilead Sciences position peaked at $1.97M in Q2 2016.
- 1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.
Based on Bragg Financial Advisors's 13F filing for Q1 2023, filed 15 May 2023.